Isoptin Khk Retard (Verapamil Hydrochloride)

Isoptin Khk Retard, a calcium channel blocker, is indicated for several cardiovascular conditions.

• Hypertension: reduces systemic vascular resistance to lower blood pressure.
• Angina pectoris: decreases myocardial oxygen demand and improves coronary blood flow.
• Supraventricular tachyarrhythmias: slows atrioventricular nodal conduction to control heart rate.

• Verapamil hydrochloride blocks L‑type calcium channels in cardiac myocytes, vascular smooth muscle, and the sino‑atrial and atrioventricular nodes. By inhibiting calcium influx, it reduces myocardial contractility, prolongs AV nodal refractory period, and promotes peripheral vasodilation, which together lower blood pressure, relieve anginal chest pain, and control rapid supraventricular rhythms. The drug’s effect on the conduction system also contributes to its antiarrhythmic properties, while its vascular action helps to decrease afterload.

Verapamil hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Constipation: reduced gastrointestinal motility.
• Dizziness or light‑headedness: related to blood pressure lowering.
• Headache: vascular dilation in cerebral vessels.
• Peripheral edema: fluid accumulation in lower limbs.
• Nausea: upset stomach and possible vomiting.

Serious or Rare Side Effects

• Severe bradycardia: markedly slowed heart rate.
• Heart block: impairment of AV nodal conduction.
• Hypotension: significant drop in blood pressure that may cause fainting.
• Liver enzyme elevation: abnormal hepatic function tests.
• Lactic acidosis (rare): metabolic disturbance requiring immediate medical attention.

When prescribing Isoptin Khk Retard, clinicians should observe several precautionary measures to ensure patient safety.

• Cardiovascular assessment: evaluate for existing heart block, severe left ventricular dysfunction, or hypotension before initiation.
• Concomitant beta‑blocker use: monitor for excessive bradycardia or AV block.
• Renal or hepatic impairment: adjust dosing and monitor drug levels as clearance may be reduced.
• Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited.
• Drug‑specific monitoring: obtain baseline ECG and periodic follow‑up to detect conduction abnormalities.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Verapamil hydrochloride interacts with several medications; awareness of the interaction level guides clinical management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause toxic verapamil concentrations.
• Digoxin: increased serum digoxin levels leading to toxicity.
• Beta‑blockers: additive negative chronotropic and inotropic effects, risking severe bradycardia.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce verapamil efficacy.
• Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): increased risk of myopathy.
• Antacids containing aluminum or magnesium: may decrease oral absorption of verapamil.